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INTRODUCTION
The limitations of the most obvious and trusted drug 
delivery techniques, such as conventional drug delivery 
system (DDS), have been recognized for some time now, 
the most important limitation of them being the patient 
incompliance due to frequent medication. This limitation can 
be overcome by modifying existing DDS. An appropriately 
designed sustained release (SR) or controlled release DDS 
can be a major step toward solving the problem associated 
with conventional DDS.  [1,2] The SR DDS also have solutions 
for other limitations of the conventional DDS such as 
undesirable side effects due to fluctuating plasma drug level, 
inability to maintain adequate drug concentration in plasma 
for therapeutic effect, larger doses than those required 
by the cells have to be administered in order to achieve 
the therapeutic concentration, causing the undesirable, 
toxicological and immunological effects in non-target tissues.
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The objective of the current investigation is to reduce dosing frequency and improve patient compliance by 
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Some drugs are readily absorbed from the GI tract, 
but easily eliminated from the body via excretion on 
account of its short half-life, requiring concomitant drug 
administration. Formulating an oral controlled release 
dosage form for these classes of drugs can be most 
beneficial as they release drug slowly in GIT and maintain 
constant drug levels in plasma for the extended period.[3] 
SR dosage forms, based on multiparticulate systems have 
attracted much attention due to their several benefits in 
reducing risk of dose dumping, and local irritation as the 
individual units can pass randomly through the pylorus 
and distribute widely in the GI tract[4] producing more 
predictable drug release profiles.
Glipizide is one of the most rapid and short acting 
second-generation  blood-glucose-lowering  drug 
belonging to class of sulphonylurea[5] and specially used 
in type II diabetes (non-insulin-dependent diabetes 
mellitus). The recommended dose range is 2.5-20 mg 
daily.[5] The absolute bioavailability is close to 1, thus 
it belongs to Biopharmaceutical Classification System 
(BCS) Class 2.[6] Gastrointestinal absorption of Glipizide 
is uniform, rapid, and essentially complete with 
relatively short elimination half life (3.4 6 0.7 h).[7] The 
development of controlled release dosage forms thus, 
would clearly be advantageous. The characteristics of the 
drug such as short half life, low dose, and therapeutic 
use in chronic disease make it a suitable candidate for 
sustained release formulation.
The objective of the present invention is to develop and 
evaluate a sustained release microparticulate system of 
Glipizide in order to extend the drug release for about 
12 h of duration and. The microspheres were evaluated 
for particle size, densities, flow properties, morphology, 
recovery yield, drug content, and in vitro drug release 
behavior.
MATERIALS AND METHODS
Materials
The active ingredient Glipizide was obtained as gift 
sample from Cipla Pharmaceuticals, Mumbai. Eudragit® 
S100 was procured from Evonik Degussa India Pvt. 
Ltd., Mumbai and Ethyl cellulose from Central Drug 
House (P) Ltd., New Delhi. Polyvinyl alcohol (PVA) 
was obtained from Research Lab., Mumbai. Ethanol, 
n-butanol, and dichloromethane used were of analytical 
grade purchased from S.D. Fine chemicals Limited, 
Mumbai, India. Double distilled water was used 
throughout the study.
Methods
Formulation of  sustained release Glipizide microspheres
Before initiating formulation of microspheres, compatibility 
of Glipizide with different excipients was studied using the 
techniques like compatibility test for solid dosage form on 
lab scale[8] and DSC testing. Excipients used in formulation 
batches were found to be compatible with Glipizide.
Formulation of drug-loaded microspheres was carried out 
by the emulsion solvent diffusion-evaporation method. The 
polymers ethyl cellulose and Eudragit® S100 were used in 
different ratios with formulation batches F1 to F5, these 
ratios were shown in Table 1. The preferred ratio of 1:19 
of Glipizide to polymer was used for all batches. Initially a 
solvent mixture of ethanol: dichloromethane: n-butanol was 
prepared in the ratio of 8:5:2 considering their volumes. An 
accurately weighed quantity of Glipizide (50 mg) and enteric 
polymer Eudragit® S100 along with ethyl cellulose was co-
dissolved at room temperature in a solvent mixture. This 
solution was introduced into 1000 ml of 0.4% PVA aqueous 
solution at room temperature and dispersed to form 
emulsion at stirring rates of 200 rpm using a mechanical 
stirrer equipped with 4-blade propeller. Agitation provided 
by stirrer breaks the poured polymer solution to form an 
oil-in-water (O/W) type emulsion. This emulsion was then 
stirred for about 20 min at room temperature. After stirring, 
the solidified microspheres were recovered by filtration, 
washed with phosphate buffer (pH 7.4 6 1) to remove all 
non-encapsulated drug, and further with distilled water to 
wash off PVA solution. Recovered microspheres were dried 
at 508C for 12 h to remove solvents. 
Evaluation of microspheres
Micromeritic properties
Microspheres were characterized for their micromeritic 
properties such as particle size, shape, bulk density, tapped 
density, compressibility index, Hausner’s ratio, and angle of 
repose. The size was measured using an optical microscope 
with the help of a calibrated ocular and stage micrometer, 
Table 1: Formulae of Glipizide microspheres with variable 
polymer ratios
Formulation 
batches*#
Ratio of ethyl 
cellulose to 
Eudragit® S100 
Quantity of polymer 
used (mg)
Quantity of 
Glipizide 
(mg) Ethyl 
cellulose
Eudragit® 
S100
F1 1:0 950  0 50
F2 1:1 475 475 50
F3 2:3 380 570 50
F4 1:4 190 760 50
F5 0:1 0 950 50
*Stirring carried out at room temperature; #Ratio of solvent used in each formulation 
was 8:5:2 (Ethanol:DCM:n-butanol)J Young Pharm Vol 2 / No 1  37
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and the particle size range was obtained by measuring size 
of about 100 particles.[9]
Densities were derived as follows: An exact quantity ‘ M ’ 
of microsphere was taken and was placed into a measuring 
cylinder. Volume ‘ V ’ occupied by the microspheres was 
noted without disturbing the cylinder and bulk density was 
calculated using the following equation;[9] 
Bulkdensity
M
V
( ) Pb =
The tapping method was used to determine the tapped 
density in which the cylinder containing known amount (M) 
of microspheres was subjected to a fixed number of taps 
(approximately 100) until the bed of microspheres had reached 
the minimum. The final volume after tapping ‘Vo’ was recorded 
and the tap density was calculated by the following equation:
Tappeddensity
M
V
( ) Pp =
o
Angle  of  repose,  Hausner  ratio,  and  Carr  index 
(% compressibility index) were determined to predict 
flowability. A higher Hausner ratio indicates greater cohesion 
between particles, while a high Carr index is indicative of 
the tendency to form bridges. Angle of repose[9] of the 
microspheres, is the maximum angle possible between the 
surface of the pile of microspheres and the horizontal plane, 
was obtained by fixed funnel method using the formula;
Angleof repose =tan
2h
d
( ) 
− 

  


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Where, h is height and d is the diameter of the microsphere 
pile that is on a paper after making the microspheres flow 
from the glass funnel.
Hausner ration and Carr index were calculated using the 
formulae:
Carrindexor%compressibilityindexorC
V
V
o = −








× 1 100
Hausnerratio=
100
100+C
Here, V and Vo are the volumes of the sample before and 
after the standard tapping, respectively and C is Carr index.
Morphology
The surface topography, particle size, morphology, and 
internal cross-sectional structure of the microspheres 
were explored by using the technique like scanning 
electron microscopy (SEM).[10] The ultra-structural features 
were analyzed by JEOL Scanning Electron Microscope 
(JSM-5400). Before the samples were analyzed, dry 
microspheres were placed on an electron microscope brass 
stub and coated with gold in an ion sputter. Pictures of 
microspheres were taken by random scanning of the stub.
Percent recovery yield and encapsulation efficiency of  microspheres
Percent recovery yield[10] of microspheres was calculated 
from the formula:
%Yield=
Totalweightof microspheres
Totalweightof drug,
polymeran ndotherexcipientsif added














×100
Encapsulation efficiency of the microspheres was evaluated 
by deriving percent drug encapsulation. The drug content 
of drug-loaded microspheres was determined by dispersing 
100 mg of microspheres in 50 ml ethanol followed by 
agitation with a magnetic stirrer for about 30 min to 
dissolve the polymer and to extract the drug. After filtration 
through a 5 mm membrane filter, the drug concentration 
in the ethanol phase was determined by taking the 
absorbance of this solution spectrophotometrically 
at 276 nm. Eudragit® S100 and ethyl cellulose did not 
interfere under these conditions. Drug concentration was 
then calculated. Thus, the total drug encapsulated in total 
yielded microspheres from the procedure was calculated. 
It was expressed in percentage called as “Percent drug 
encapsulation” calculated as:
%Drug encapsulation =
Actual drug content
Theoretical drug co ontent







×100
In vitro drug release studies and comparison of  release profile with 
marketed formulation
The drug release rate from microspheres was determined 
using USP XXIV basket-type dissolution apparatus.  [11] 
A weighed amount of microspheres equivalent to 5 mg drug 
was filled into a capsule (size 0) and placed in the basket. 
Dissolution medium used was 0.1 N HCl (pH 1.2, 900 ml) 
for first hour and maintained at 37 6 0.58C at a rotation 
speed of 100 rpm. Prefect sink conditions prevailed during 
the drug release studies. 5 ml of sample was withdrawn 
at each 1 h interval; later this interval was extended to 
2 h. Sample was then passed through a 5 mm membrane 
filter, and analyzed spectrophotometrically at 276 nm 
to determine the concentration of drug present in the 
dissolution medium. The initial volume of dissolution 
medium was maintained by adding 5 ml of fresh 
dissolution media after each withdrawal. The dissolution 
study was continued with using simulated intestinal fluid 
(pH 7.5 6 1, 900 ml) for next 12 h. All experiments were 
conducted in triplicate.38   J Young Pharm Vol 2 / No 1
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RESULT AND DISCUSSION
Formation of microspheres
In the formulation of Glipizide microspheres, Eudragit® S100 
and controlled release polymer ethyl cellulose polymers were 
used, and mixture of ethanol, dichloromethane, and n-butanol 
was chosen as the solvent system. After introduction of drug 
and polymer solution in the aqueous PVA solution, an oil-
in-water emulsion gets formed. Agitation provided by stirrer 
breaks the poured polymer solution into discrete droplets, 
forming an oil-in-water (O/W)-type emulsion where polymer 
and drug were still in their solution form in organic solvent. 
In the emulsion, the organic dispersed phase was drug with 
polymer solution and aqueous dispersion phase was PVA 
solution. As the stirring continued, the ethanol and n-butanol 
started to diffuse out from organic phase to aqueous phase, 
co-precipitating the drug and polymer at the interface of 
emulsion droplet. This co-precipitation of drug and polymer 
resulted into a shell around droplet. Dichloromethane 
remained entrapped within the shell of the droplet.
Kawashima et al.,[12] reported that when the diffusion rate 
of solvent from the organic phase emulsion droplet was too 
slow, microspheres coalesced together. In another study,[13] 
he reported that when it was too fast; the solvent may diffuse 
into the aqueous phase before stable emulsion droplets 
were formed, causing the aggregation of embryonic 
microspheres droplets. Here, incorporation of n-butanol 
in the solvent system declined the rate of diffusion of 
solvent into outer phase to achieve the critical diffusion 
rate. Appropriate rate of solvent diffusion gave desired 
porosity and morphology of microspheres. The alteration 
in this diffusion rate was due to different molecular weight 
of solvents. Higher the molecular weight, more time it will 
take to diffuse. Slower diffusion rate of n-butanol than that 
of ethanol provides more time for diffusion and ultimately 
for droplet formation. It improved the yield and decreased 
the losses due to aggregation of non-spherical emulsion 
droplets caused by rapid solvent diffusion. Apart from this, 
Lee et al.[14] had made another such effort in which ethanol 
was replaced by isopropanol to improve the method of 
microsphere preparation by controlling the diffusion rate 
of solvent, and the effect on the formation of microspheres 
was evaluated. In this study, it was also reported that yield 
of microspheres depended on the diffusion rate of ethanol 
and/or isopropanol into the aqueous phase. Kawashima 
et al.[15] documented that the stable formation of an O/W 
emulsion at the initial stage and the precipitation of 
polymer on the surface of the dispersed droplet were the 
key elements in formulation of microspheres with desirable 
morphological characteristics. 
Larger amount of aqueous dispersion phase (1000 ml) 
was used with the intension to harden the microspheres 
in shorter period of time. As reported by Jain et al.,[10] 
using larger amounts of aqueous phase (400-500 ml), the 
diffusion of dichloromethane into the aqueous phase and 
hence solidification of particles occurs faster as compared 
to 200 ml. Thus, using large volumes of aqueous phase had 
potential advantage of reduction in required stirring times. 
Hence, diffusion of the organic solvents completed in the 
time span of 20 min and the microspheres get hardened.
Micromeritic properties
Microspheres were found to be spherical and discrete. 
But the particle size of microspheres varied in range. 
The particle size increased with increase in ethyl cellulose 
concentration. The particle sizes of various batches of 
microspheres were in the range of 71mm to 474mm. 
Particle size range, densities, and flow properties of 
microspheres of batches F1-F5 are shown in Table 2. 
Flow properties of batches were evaluated by measuring the 
angle of repose and compressibility index. In the evaluation 
of flowability of dry solid, the substance shows excellent 
flowability and performance, when the angle of repose have 
the value less than 25º, while when compressibility index has 
value below 9%, no aid is needed for enhancing the flowability 
of powder.[16] Thus, angle of repose and compressibility index 
are indicative of good flowability of microspheres, showing 
no need for addition of glidants to enhance flowability. The 
better flow property of microspheres indicates that the 
microspheres produced were non-aggregated. The improved 
micromeritic properties of formulated microspheres when 
compared to that of the pure drug alone suggest that they 
can be easily handled and filled into a capsule. 
Table 2: Effect of various polymer ratios over micromeritic properties of microspheres
Formulation 
codes
Particle size range 
(mm)
Bulk density* 
(g/ml)
Tapped density* 
(g/ml)
Angle of repose* 
(degrees)
% Compressibility* Hausner’s 
ratio*
F1 142-474 0.324 6 0.009 0.346 6 0.009 21.52 6 1.911 6.37 6 1.720 1.056 6 0.041
F2 113-457 0.339 6 0.012 0.359 6 0.007 21.68 6 1.785 6.51 6 1.913 1.061 6 0.058
F3 92-422 0.341 6 0.016 0.361 6 0.011 21.18 6 1.613 6.55 6 1.896 1.047 6 0.068
F4 86-326 0.348 6 0.009 0.375 6 0.009 22.47 6 1.574 6.69 6 2.045 1.072 6 0.034
F5 71-289 0.351 6 0.011 0.382 6 0.006 21.55 6 2.148 6.73 6 1.843 1.067 6 0.037
*Average of three preparations 6 SDJ Young Pharm Vol 2 / No 1  39
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Morphology
Surface properties and internal structure of microspheres 
had been revealed by scanning electron microscopy 
(SEM). The microphotographs of cross section and 
surface view of microspheres of batch F3 are shown in 
Figures 1 and 2.
The cross-sectional photomicrograph of the microspheres 
are shown in Figure 1, part (A) shows the round cavity 
surrounded by the thick shell of the microspheres, 
while part (B) shows the thick shell having about 80 
mm length. Smooth outer surface of the microspheres 
appearing from the part (B) of the Figure 2 indicates no 
precipitation of drug on the surface of microspheres. 
SEM indicated that the microspheres produced by the 
emulsion solvent diffusion-evaporation method are 
spherical with smooth surface and not aggregated. Their 
smooth surface indicated that Glipizide was embedded 
in the shell, as the drug particles were not present on 
the surface.
Percent recovery yield and encapsulation efficiency 
of microspheres
Percent recovery yield was found to be increased from 
batches F1 to F5 with an increase in concentration of 
Eudragit® S100. It ranges from 74.81% to 96.26%, with 
highest recovery yield with batch F5. Percent recovery yield 
and percent encapsulation efficiency of the batches F1-F5 
are shown in Table 3.
The effect of the combination of the polymers over 
encapsulation efficiency was convincing. The encapsulation 
Figure 2: Scanning electron photomicrographs of Glipizide-loaded microspheres with surface view, (a) resolution 75 times, (b) resolution 350 times.
Figure 1: Scanning electron photomicrographs of Glipizide-loaded microspheres with cross-sectional area, (a) resolution 200 times, (b) resolution 
500 times. 
Table 3: Effect of various polymer ratios on characteristics 
of microspheres
Formulation 
batches
% Recovery 
yield*
% Encapsulation 
efficiency*
% Drug release 
at 12th hour*
F1 74.81 6 2.72 30.12 6 2.23 25.19 6 1.58
F2 86.18 6 3.02 78.91 6 2.34 72.18 6 2.11
F3 89.12 6 3.41 94.84 6 2.41 96.76 6 2.58
F4 94.14 6 2.82 67.37 6 2.06 99.54 6 2.18
F5 96.26 6 2.15 26.79 6 2.57 100.91 6 2.86
*Average of three preparations 6 SD40   J Young Pharm Vol 2 / No 1
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efficiency was found to be abruptly increasing when both 
polymers were used together. Encapsulation efficiencies of 
batches F1-F5 ranged from 26.79% to 94.84%. Maximum 
encapsulation efficiency was observed of the batch F3, 
where ratio of 2:3 of the ethyl cellulose and Eudragit® 
S100 was used. It was about three times higher than that 
of batches F1 and F5 where ethyl cellulose and Eudragit® 
S100 were used alone, respectively. This ratio of polymers 
was found to be the efficient of encapsulating maximum 
drug than any other batches. 
It was reported in the literature that the encapsulation 
efficiency depends on the solubility of the drug in 
the solvent and continuous phase. An increase in the 
concentration of polymer in a fixed volume of organic 
solvent resulted in an increase in encapsulation efficiency.  [17] 
As we have seen in the formulation, alcohol diffused out 
first to the external aqueous phase, thus when the drug was 
soluble in alcohol, it was possible that the drug may diffuse 
out of emulsion droplets together with alcohol before the 
droplet solidification, leading to a low loading efficiency. 
This tendency of the drug would become more prominent 
when the solubility of the drug in dichloromethane was low, 
since the drug preferentially partition into the alcohol phase 
when it moved into aqueous phase from a solvent mixture. 
In contrast to this condition, the drug Glipizide was water 
insoluble, along with that Glipizide was practically insoluble 
in alcohol and soluble in dichloromethane[18] showing 
greater encapsulation efficiency. 
In vitro drug release studies
Different release profiles were observed with each 
combination of polymers. The effect of changes in 
polymer proportion in batches F1 to F5 has been shown 
in Table 3 and Figure 3. When ethyl cellulose alone was 
used (F1), no drug release was observed till 8th hour of 
dissolution study. The reason for this may be the insolubility 
in water and hydrophobicity of the ethyl cellulose.[19] 
When 1:1 proportion of ethyl cellulose: Eudragit® S100 
was used (F2), 70-75% drug release was observed in 12 h. 
This batch was controlling drug release more than 12 h. In 
batch F4, total drug release observed merely after 8 h. 
Eudragit® S100 alone gave formulation (F5) which released 
the entire drug only in 4-5 h. One of these formulations 
(F3) prepared using 2:3 ratio of polymer (Ethyl cellulose: 
Eudragit® S100) gave the most satisfactory results with 
extended drug release for approximately 12 h and highest 
encapsulation efficiency. Figure 3 had shown that increase 
in concentration of ethyl cellulose decreased the drug 
release rate. The appropriate combination of these two 
polymers had been achieved in batch F3 where extended 
release of drug for approx. 12 h had been attained. 
The results of the in vitro drug release study obtained from 
batch F3 were plotted using kinetic models. Zero-order kinetics, 
first-order kinetics, Higuchi’s matrix, Korsmeyer Peppas model, 
and Hixson Crowell kinetic model were used to evaluate the 
release mechanism from Glipizide microspheres. The kinetic 
model showing highest correlation coefficient was considered 
as the most appropriate model for the dissolution data. The 
best fit with the highest correlation coefficient was observed in 
the Korsmeyers-peppas model and zero-order release kinetics 
followed by Higuchi model, as given in Table 4. The ‘n’ value 
of formulation was found to be 0.960 indicating that the drug 
release was followed by anomalous (non-fickian) diffusion.
CONCLUSION
In this study, stable sustained release Glipizide microspheres 
were prepared successfully using the emulsion solvent 
diffusion-evaporation method. This study has been a 
satisfactory attempt to formulate a microparticulate system 
of an anti-diabetic drug Glipizide with a view of sustained 
delivery of the drug. Moreover, the developed product is 
less complex with regards to formulation components and 
processing aspects. 
It may be concluded that capsules of sustained release 
Glipizide microspheres would be a promising drug delivery 
system for oral administration of Glipizide to sustain the 
Figure 3: In vitro drug relase study of batches F1(-♦-), F2(-■-), F3(-▲-), 
F4(-●-), F5(-x-). Reproduction size should be column width
Table 4: ‘r2’ values of various kinetic models and value 
of ‘n’
Kinetic 
models
Zero 
order
First 
order
Higuchi Hixon 
crowell
Korsmeyers-
peppas
r  2 r  2 r  2 r  2 r  2 n
0.988 0.941 0.970 0.954 0.989 0.960J Young Pharm Vol 2 / No 1  41
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drug release for about 12 h enhancing the patient compliance. 
In the formulation, the combination of cost-effective and 
biocompatible polymers Eudragit® S100 and Ethyl cellulose 
had been successfully used and there is scope of scale up of 
the batches to the commercial level. The formulation was 
found to be efficient with good recovery yield and percent 
drug entrapment. The surface structure, particle size, and 
flow analysis revealed that the microspheres showed good 
flow and packability, indicating that it can be successfully 
handled and filled into a capsule dosage form. 
Hence, the SR microsphere formulation of Glipizide 
may provide a convenient dosage form for achieving best 
performance regarding flow, drug entrapment, and release. 
Further, their potential to improve Glipizide bioavailability 
in humans needs to be investigated in further studies. 
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